About BIOC

Biocept, Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer. Biocept's patented technology platform captures and analyzes circulating tumor DNA, both in CTCs and in plasma (ctDNA). Biocept currently offers assays for gastric cancer, breast cancer, lung cancer, colorectal cancer and melanoma, and plans to introduce CLIA-validated assays for prostate cancer and other solid tumors in the near term.
Primary Exchange: NASDAQ
SIC Services-Commercial Physical & Biological Research
NAICS Medical Laboratories

BIOC is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
ITOT iShares Core S&P Total U.S. Stock Market ETF 16.5 B 1.65381E+10 3,387 3387 0.0% 0 4 K 4430
WMCR Invesco Wilshire Micro-Cap ETF 21.7 M 2.17E+07 1,083 1083 0.01% 8E-05 2 K 1732

Wait, Before You Leave...